ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
Dow Jones
38.675,68
1,18%
Euro vs US Dollar
1,07725
0,00%
Bitcoin
63.162,98
-1,14%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Verastem Inc (VSTM)

  7. Verastem Inc (VSTM) News

VSTM

Verastem (VSTM)

Verastem Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:VSTM
DatumZeitQuelleÜberschriftSymbolFirma
18/04/202422h05Business WireVerastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical OfficerNASDAQ:VSTMVerastem Inc
04/04/202413h30Business WireVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VSTMVerastem Inc
18/03/202412h00Business WireGlobal Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian CancerNASDAQ:VSTMVerastem Inc
14/03/202421h05Business WireVerastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business UpdatesNASDAQ:VSTMVerastem Inc
11/03/202422h07Edgar (US Regulatory)Form SC TO-I/A - Tender offer statement by Issuer: [Amend]NASDAQ:VSTMVerastem Inc
11/03/202412h30Business WireVerastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet NeedsNASDAQ:VSTMVerastem Inc
05/03/202423h27Business WireVerastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian CancerNASDAQ:VSTMVerastem Inc
05/03/202422h30Business WireVerastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024NASDAQ:VSTMVerastem Inc
08/02/202422h22Edgar (US Regulatory)Form SC TO-I - Tender offer statement by IssuerNASDAQ:VSTMVerastem Inc
02/02/202415h49Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VSTMVerastem Inc
29/01/202422h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VSTMVerastem Inc
29/01/202413h00Business WireVerastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven CancersNASDAQ:VSTMVerastem Inc
19/01/202413h54Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VSTMVerastem Inc
18/01/202422h00Business WireVerastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)NASDAQ:VSTMVerastem Inc
11/01/202413h00Business WireVerastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology ConferenceNASDAQ:VSTMVerastem Inc
09/01/202422h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VSTMVerastem Inc
08/01/202422h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VSTMVerastem Inc
05/01/202413h00Business WireVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VSTMVerastem Inc
28/12/202322h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VSTMVerastem Inc
21/12/202322h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VSTMVerastem Inc
20/12/202322h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VSTMVerastem Inc
20/12/202322h00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VSTMVerastem Inc
19/12/202322h01Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:VSTMVerastem Inc
18/12/202313h00Business WireVerastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet TherapeuticsNASDAQ:VSTMVerastem Inc
13/12/202313h00Business WireVerastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian CancerNASDAQ:VSTMVerastem Inc
08/12/202322h10Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:VSTMVerastem Inc
21/11/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:VSTMVerastem Inc
13/11/202313h00Business WireNew Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment ApproachNASDAQ:VSTMVerastem Inc
08/11/202323h01Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:VSTMVerastem Inc
08/11/202322h16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VSTMVerastem Inc
 Showing the most relevant articles for your search:NASDAQ:VSTM

Kürzlich von Ihnen besucht

COIN
ETHUSD
Ethereum
NYSE
JPM
JP Morgan Chase
USOTC
DTEGY
Deutsche Telekom (QX)
TG
BAYN
Bayer
TG
MBG
MercedesBenz
CCOM
US100
US Tech 100
TG
432
Arbor Metals
NYSE
DIS
Walt Disney
DBI
DAX
DAX
USOTC
BASFY
BASF (QX)
COIN
BTCUSD
Bitcoin
PM
XAUUSD
Gold vs US Dollar
USOTC
BNPQY
BNP Paribas (QX)
NASDAQ
AAPL
Apple
FX
EURJPY
Euro vs Yen
TG
ALV
Allianz
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten